Ascendis Pharma A/S
ASND
147 hedge funds and large institutions have $5.45B invested in Ascendis Pharma A/S in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 44 increasing their positions, 58 reducing their positions, and 22 closing their positions.
133% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $21.8M
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
4.16% more ownership
Funds ownership: 96.67% → 100.83% (+4.2%)
3% more funds holding
Funds holding: 143 → 147 (+4)
15% less capital invested
Capital invested by funds: $6.42B → $5.45B (-$969M)
24% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 58
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$260M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$94.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$79.8M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$52.4M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$51.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73.9M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$37.7M |
| 3 |
Millennium Management
New York
|
-$28.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.7M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.5M |
ASND Hedge Fund Activity: Q1 2020 in Review
147 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2020, worth a combined $5.45B — down 15% from $6.42B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ASND positions and 22 closed out — a net gain of 5 holders — while 44 added to existing stakes and 58 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $260M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.9M.
- 147 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2020, up from 143 in Q4 2019.
- Funds reported $5.45B of Ascendis Pharma A/S stock for Q1 2020, down 15% quarter-over-quarter.
- 27 funds opened new Ascendis Pharma A/S positions in Q1 2020 and 22 closed out, a net change of +5 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2020 was Vivo Capital, an estimated $260M added.
- The largest Ascendis Pharma A/S seller in Q1 2020 was T. Rowe Price Associates, an estimated $73.9M sold.
Based on aggregated 13F filings for Q1 2020.